Prospective population  Inclusion Criteria:  Patients aged 19 years or older and histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma Patients with locally advanced or metastatic disease for which curative resection is not possible. Patients who have failed fluoropyrimidine and platinum (cisplatin or oxaliplatin)-based chemotherapy as palliative first-line therapy Patients who is starting ramucirumab/paclitaxel combination therapy after the study initiation date  Exclusion Criteria:  Patients receiving ramucirumab monotherapy Patients receiving ramucirumab/paclitaxel in clinical trial or receiving without being covered by health insurance Patients unable to communicate or incapable of understanding documents for patient report outcomes Historical retrospective population  Inclusion Criteria:  Patients aged 19 years or older and histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma Patients with locally advanced or metastatic disease for which curative resection is not possible Patients who have failed platinum-based palliative first-line therapy, and who started the following second-line therapy: taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy, before May 1, 2018  Exclusion Criteria:  Patients receiving ramucirumab monotherapy Patients receiving ramucirumab/paclitaxel in clinical trial or receiving without being covered by health insurance